For deal-making trends, deals are grouped into three main categories: gene therapy, cell therapy and tissue regeneration. There may be overlap among the categories in terms of deals included in each if they cross over more than one of those categories. The sources for these data are Informa's Medtrack and Strategic Transactions. The regenerative medicine industries covered from Medtrack include biomaterials and tissue regeneration (which were included in the tissue regeneration category), in vivo and ex vivo gene therapy (in the gene therapy category) and stem cell therapy (in the cell therapy category). Within Medtrack's partnership classification are funding/grant announcements, as well as some deals focused on the veterinary market. The regenerative medicine industries covered from Strategic Transactions include "gene therapy, cell therapy" and biomaterials. The deals labeled "gene therapy, cell therapy" were individually reviewed and placed into one or more of the three main categories. The biomaterials deals were included in the tissue regeneration category. Keyword searching of deal summaries was also used in Strategic Transactions to identify regenerative medicine deals. Gene editing deals are included in the gene therapy category.
Methodology: Regenerative Medicine Deals
The methodology behind Datamonitor Healthcare's new Regenerative Medicine Landscape report.
More from Archive
More from In Vivo
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.